-
Mashup Score: 38Is Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma a Disease-Modifying Therapy? - 4 month(s) ago
Retrospective and prospective studies have shown that SABR can be safely combined with immunotherapy, delay initiation of systemic therapy, and control progressing lesions without changing systemic therapy in patients with oligometastatic RCC. Larger randomized trials are needed to consolidate the role of SABR in this space.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Deciphering Immunotherapy Responses in Advanced RCC: A Deep Dive into the HCRN Study - Nourhan El Ahmar - 7 month(s) ago
Pedro Barata interviews Nourhan El Ahmar to discuss the significant work conducted by El Ahmar’s team. The work focused on a subgroup analysis of the HCRN GU16-260 platform study that investigated the use of nivolumab with ipilimumab as salvage therapy for patients with advanced renal cell carcinoma. El Ahmar delves into the specifics of the trial, explaining how their lab played a crucial role…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Deciphering immunotherapy responses in advanced #RCC: a deep dive into the HCRN study. Join @Nourhanelahmar @BrighamWomens and @PBarataMD @caseccc in discussing a subgroup analysis of the HCRN GU16-260 platform study, of nivo and ipi as salvage therapy > https://t.co/ky92Q1YAsu https://t.co/NIRu98LQ5N
-
-
Mashup Score: 6Tumor Board Tuesday 2023 Conversations - 7 month(s) ago
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
Source: integrityce.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0Dovitinib Companion Diagnostic Shows Results in RCC - 7 month(s) ago
The tool shows promise to predict a patient’s response to dovitinib to better inform treatment options for patients with renal cell carcinoma and other solid tumors.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel George, MD, discussed the CheckMate 9ER trial in terms of bone, liver, and lung metastases and other subgroups in patients with advanced clear cell renal cell carcinoma.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Renal Cell Carcinoma: 5 Things to Know for Primary Care - 7 month(s) ago
Cues and clues to renal cell cancer might be found in modifiable or innate patient factors. These 5 things to know for primary care might tip off timely testing or a potentially life-saving referral.
Source: www.medscape.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Renal Cell Carcinoma: 5 Things to Know for Primary Care - 7 month(s) ago
Cues and clues to renal cell cancer might be found in modifiable or innate patient factors. These 5 things to know for primary care might tip off timely testing or a potentially life-saving referral.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0SABR Yields ’Exceptional‘ Outcomes in Older Patients With Inoperable Renal Cell Carcinoma - 7 month(s) ago
Older patients with kidney cancer experienced “exceptional” disease control with stereotactic ablative radiotherapy—which is noninvasive and occurs in the outpatient setting.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1SABR Yields ’Exceptional‘ Outcomes in Older Patients With Inoperable Renal Cell Carcinoma - 7 month(s) ago
Older patients with kidney cancer experienced “exceptional” disease control with stereotactic ablative radiotherapy—which is noninvasive and occurs in the outpatient setting.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In the first article of a 2-part series, Benjamin Garmezy, MD, discusses risk stratification and combination options in the metastatic clear cell renal cell carcinoma setting.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Check out our commentary on SBRT for metastatic #RCC written by our newest faculty member @MDAndersonNews, Osama Mohamad, coauthored with @Raquib_Hannan from @utswcancer. @KidneyCancer @PavlosMsaouel @ndesai2005 @_ShankarSiva https://t.co/SMJROpoEzU